Recently there has been great interest in the development of precision medicines that target a specific underlying disease mechanism so that responders will have a better therapeutic response and less adverse effects compared with the nonspecific therapies that are currently used. Peter Barnes is Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London.
Image courtesy of interviewee
